Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 5/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971736 | 1.00 | HPGD (0.42) | HPGDAKR1B1PIM1PIM2NPC1 | |
| Hydrochloric Acid SCHEMBL3963508 | 0.99 | HPGD (0.41) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3966072 | 0.92 | HPGD (0.45) | HPGDAKR1B1PIM1PIM2CISD1 | |
| SCHEMBL6242980 | 0.92 | PPARG (0.41) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL13868974 | 0.87 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3964115 | 0.87 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| Hydrochloric Acid SCHEMBL4211139 | 0.86 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3965304 | 0.86 | REN (0.42) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL4206795 | 0.82 | HPGD (0.50) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL13868976 | 0.82 | HPGD (0.50) | HPGDAKR1B1PIM1PIM2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521466-B2 | Dipeptide phenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | NAG BISHWAJIT | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037863-A1 | such as 5-[4-(4-(2-(2-amino-3-imidazol-4-yl propanamido)-2-methoxy carobonylethyl)phenoxy)benzylidene]thiazolidin-2,4-dione, used for lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels; prophylaxis of diabetes, obesity, inflammation and autoimmune diseases | FFAR4, IAPP, FFAR2 | HPGD 4199/4885AKR1B1 3293/4885PIM1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.